Urologic Oncology: Seminars and Original Investigations
Volume 26, Issue 2 , Pages 125-132, March 2008

Consumption of dietary supplements and over-the-counter and prescription medications in men participating in the Prostate Cancer Prevention Trial at an academic center

  • Elizabeth M. Grainger, Ph.D.

      Affiliations

    • Department of Internal Medicine, Division of Hematology and Oncology, Ohio State University, Columbus, OH 43210, USA
  • ,
  • H. Sunny Kim, Ph.D.

      Affiliations

    • School of Public Health, Center for Biostatistics, Ohio State University, Columbus, OH 43210, USA
  • ,
  • J. Paul Monk, M.D.

      Affiliations

    • Department of Internal Medicine, Division of Hematology and Oncology, Ohio State University, Columbus, OH 43210, USA
  • ,
  • Stanley A. Lemeshow, Ph.D.

      Affiliations

    • School of Public Health, Center for Biostatistics, Ohio State University, Columbus, OH 43210, USA
  • ,
  • Michael Gong, M.D.

      Affiliations

    • Division of Urology, Department of Surgery, Ohio State University, Columbus, OH 43210, USA
  • ,
  • Robert R. Bahnson, M.D.

      Affiliations

    • Division of Urology, Department of Surgery, Ohio State University, Columbus, OH 43210, USA
  • ,
  • Steven K. Clinton, M.D.

      Affiliations

    • Department of Internal Medicine, Division of Hematology and Oncology, Ohio State University, Columbus, OH 43210, USA
    • Division of Urology, Department of Surgery, Ohio State University, Columbus, OH 43210, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-614-293-8396; fax: +1-614-293-7525.

Received 9 August 2006; received in revised form 12 January 2007; accepted 12 January 2007. published online 18 October 2007.

Abstract 

Objective

It is hypothesized that dietary patterns, individual nutrients, and specific prescription and over-the-counter medications may influence prostate carcinogenesis. Little information is available regarding the use of these products among men who are participating in prevention trials targeting prostate cancer.

Materials and methods

A total of 92 men (mean age 69 years) participating in the Prostate Cancer Prevention Trial (PCPT) at an academic center were asked to bring all nutritional supplements and medications to regularly scheduled study visits.

Results

Data were collected on 86 of 92 men. We found that 85% of men in the PCPT regularly consumed at least 1 nutritional supplement. The mean (±standard deviation) number of dietary supplements consumed per man was 3.3 ± 3.5 (range 0–21). A multivitamin and multimineral (73%) supplement was the most common product consumed. Single-nutrient supplements regularly consumed included: vitamin E (48%), vitamin C (31%), calcium (24%), and selenium (7%). Of men, 36% reported consumption of herbal products. Medications frequently consumed during the study period that may influence prostate carcinogenesis included nonsteroidal antiinflammatory drugs (57%), antihypertensives (49%), lipid lowering agents (27%), and aspirin (64%).

Conclusions

Participants in the PCPT at an academic center have a high propensity for dietary supplement use. Many, such as vitamin E and selenium, are hypothesized to influence the risk of prostate cancer. Several of the medications commonly consumed, including aspirin, nonsteroidal antiinflammatory drugs, and statins, are being investigated as chemopreventive agents. Investigators designing prostate cancer chemoprevention trials should consider including detailed documentation of exposure to these products that may influence study outcomes.

Keywords: Dietary supplements, Complementary therapy, Adult behavior, Cancer

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 This work was supported by the Ohio State University Comprehensive Cancer Center Grant P30 CA16058 and the Prostate Cancer Prevention Fund of the James Cancer Hospital and Solove Research Institute.

PII: S1078-1439(07)00013-0

doi:10.1016/j.urolonc.2007.01.016

Urologic Oncology: Seminars and Original Investigations
Volume 26, Issue 2 , Pages 125-132, March 2008